These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29625780)

  • 1. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems.
    Raschi E; Poluzzi E; Salvo F; Pariente A; De Ponti F; Marchesini G; Moretti U
    Nutr Metab Cardiovasc Dis; 2018 Jun; 28(6):533-542. PubMed ID: 29625780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
    Alkabbani W; Gamble JM
    Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
    Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
    J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
    Bonora BM; Raschi E; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2021 Feb; 20(1):39. PubMed ID: 33573667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
    Palapra H; Viswam SK; Kalaiselvan V; Undela K
    Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
    Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
    Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
    Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis.
    Gravel CA; Krewski D; Mattison DR; Momoli F; Douros A
    Br J Clin Pharmacol; 2023 Aug; 89(8):2430-2445. PubMed ID: 36912450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.
    Goldman A; Fishman B; Twig G; Raschi E; Cukierman-Yaffe T; Moshkovits Y; Pomerantz A; Ben-Zvi I; Dankner R; Maor E
    Cardiovasc Diabetol; 2023 Jan; 22(1):16. PubMed ID: 36694178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
    Zhang L; Pan C; Yang X; Jiang D; Cao M
    Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors.
    Fadini GP; Sarangdhar M; De Ponti F; Avogaro A; Raschi E
    BMJ Open Diabetes Res Care; 2019; 7(1):e000725. PubMed ID: 31641524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Butler J; Anker SD
    Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205
    [No Abstract]   [Full Text] [Related]  

  • 15. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.
    Fusaroli M; Salvo F; Begaud B; AlShammari TM; Bate A; Battini V; Brueckner A; Candore G; Carnovale C; Crisafulli S; Cutroneo PM; Dolladille C; Drici MD; Faillie JL; Goldman A; Hauben M; Herdeiro MT; Mahaux O; Manlik K; Montastruc F; Noguchi Y; Norén GN; Noseda R; Onakpoya IJ; Pariente A; Poluzzi E; Salem M; Sartori D; Trinh NTH; Tuccori M; van Hunsel F; van Puijenbroek E; Raschi E; Khouri C
    Drug Saf; 2024 Jun; 47(6):575-584. PubMed ID: 38713346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.
    Fusaroli M; Salvo F; Begaud B; AlShammari TM; Bate A; Battini V; Brueckner A; Candore G; Carnovale C; Crisafulli S; Cutroneo PM; Dolladille C; Drici MD; Faillie JL; Goldman A; Hauben M; Herdeiro MT; Mahaux O; Manlik K; Montastruc F; Noguchi Y; Norén GN; Noseda R; Onakpoya IJ; Pariente A; Poluzzi E; Salem M; Sartori D; Trinh NTH; Tuccori M; van Hunsel F; van Puijenbroek E; Raschi E; Khouri C
    Drug Saf; 2024 Jun; 47(6):585-599. PubMed ID: 38713347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.
    Honigberg MC; Vardeny O; Vaduganathan M
    Circ Heart Fail; 2020 Feb; 13(2):e006623. PubMed ID: 32059632
    [No Abstract]   [Full Text] [Related]  

  • 18. Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic study.
    Siafis S; Papazisis G
    Br J Clin Pharmacol; 2018 Oct; 84(10):2405-2414. PubMed ID: 29953643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database.
    García M; Arteche-Martinez U; Lertxundi U; Aguirre C
    J Clin Pharmacol; 2021 Feb; 61(2):187-192. PubMed ID: 32827151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.